Lynk Pharmaceuticals Announces Positive Phase III Topline Data of Zemprocitinib in Moderate-to-Severe Atopic Dermatitis - Thailand PR News - [Banking](https://thailandbusinessnews.net/category/banking/) - [Companies](https://thailandbusinessnews.net/category/companies/) - [Economy](https://thailandbusinessnews.net/category/economy/) - [Press Releases](https://thailandbusinessnews.net/category/press-release/) - [PR Newswire](https://thailandbusinessnews.net/pr-newswire-updates/) - [Tech](https://thailandbusinessnews.net/category/tech/) - [Tourism](https://thailandbusinessnews.net/category/tourism/) - [Press Release](https://thailandbusinessnews.net/category/press-release/) # Lynk Pharmaceuticals Announces Positive Phase III Topline Data of Zemprocitinib in Moderate-to-Severe Atopic Dermatitis ##### Up next ![Toku Reports US.8 million Revenue in FY2025 as AI Adoption Gains Traction; Underlying Loss Improves](https://i0.wp.com/mma.prnasia.com/media2/2922940/image1.jpg?resize=200%2C110&ssl=1 "Toku Reports US.8 million Revenue in FY2025 as AI Adoption Gains Traction; Underlying Loss Improves") [](https://thailandbusinessnews.net/press-release/toku-reports-us34-8-million-revenue-in-fy2025-as-ai-adoption-gains-traction-underlying-loss-improves/) ###### [Toku Reports US$34.8 million Revenue in FY2025 as AI Adoption Gains Traction; Underlying Loss Improves](https://thailandbusinessnews.net/press-release/toku-reports-us34-8-million-revenue-in-fy2025-as-ai-adoption-gains-traction-underlying-loss-improves/) Published on 02 March 2026 ##### Author ##### [ CISION PRNewswire ](https://thailandbusinessnews.net/author/cision/) ##### Tags - [PRNewswire](https://thailandbusinessnews.net/tag/prnewswire/) SHANGHAI, HANGZHOU, China and BOSTON, March 2, 2026 /PRNewswire/ — Lynk Pharmaceuticals Co., Ltd. ("Lynk Pharmaceuticals"), a clinical-stage innovative drug development company focused on therapies for immune and inflammatory diseases, today announced positive topline results from its Phase III clinical trial evaluating zemprocitinib in patients with moderate-to-severe atopic dermatitis (AD). The study met all co-primary and key secondary endpoints, with both dose groups demonstrating highly and statistically significant improvements versus placebo (p < 0.0001), together with a favorable safety and tolerability profile. The disclosed results represent topline data generated in accordance with the predefined statistical analysis plan. Full study data are undergoing further analysis and will be published at a future date. This study was a multicenter, randomized, double-blind, placebo-controlled Phase III clinical trial designed to evaluate the efficacy and safety of zemprocitinib in patients with moderate-to-severe atopic dermatitis. The trial was led by Professor Jianzhong Zhang and Professor Cheng Zhou of Peking University People’s Hospital. A total of 356 patients were randomized in a 1:1:1 ratio to receive zemprocitinib 12 mg, or 24 mg or placebo. The study had two co-primary endpoints at Week 16; the proportion of patients achieving ≥75% improvement from baseline in Eczema Area and Severity Index (EASI-75); and the proportion of patients achieving a validated Investigator Global Assessment for Atopic Dermatitis score of 0 (clear) or 1 (almost clear), with a ≥2-point improvement from baseline (vIGA-AD 0/1 response). The key secondary endpoint was the proportion of patients achieving a ≥4-point improvement from baseline in Worst Itch Numerical Rating Scale (WI-NRS4) at Week 16. At Week 16, both zemprocitinib dose groups demonstrated statistically significant superiority over placebo across both co-primary endpoints and the key secondary endpoint: - EASI-75: Differences versus placebo were 38.1% (12 mg) and 46.4% (24 mg) (p < 0.0001). - vIGA-AD 0/1 response: Improvements over placebo were 30.3% (12 mg) and 31.0% (24 mg) (p < 0.0001). - WI-NRS4 response rates were 31.3% (12 mg) and 31.0% (24 mg) higher than placebo at Week 16 (p < 0.0001). Zemprocitinib also achieved statistically significant improvements across multiple additional secondary endpoints, including EASI-50, EASI-90, SCORAD response rates, Dermatology Life Quality Index (DLQI), and Patient-Oriented Eczema Measure (POEM) scores, supporting broad clinical benefit in lesion clearance, symptom reduction, and quality-of-life improvement. Notably, zemprocitinib demonstrated a rapid onset of action. Improvement in pruritus was observed as early as Day 1 following initiation of therapy, with statistically significant separation from placebo in WI-NRS response rates, indicating rapid itch relief. Statistically significant improvement in EASI-75 response rates and vIGA-AD 0/1 response rates were also observed by Week 2 in both dose groups, highlighting the treatment’s early efficacy in skin lesion improvement. Zemprocitinib demonstrated a favorable overall safety and tolerability profile. The majority of treatment-emergent adverse events (TEAEs) were Grade 1–2. The incidence of serious adverse events (SAEs), adverse events of special interest (AESIs), and discontinuations due to adverse events were low and comparable to placebo, with no new safety signals observed. Laboratory findings were consistent with those observed in the Phase III rheumatoid arthritis study. No serious adverse reactions related to decreases in hemoglobin, neutrophils, or lymphocytes were observed and there were no safety concerns associated with elevations in ALT or AST. No dose-dependent differences in the safety profile were observed. Overall, the safety profile was consistent with our prior clinical studies and demonstrated competitive characteristics relative to other reported JAK inhibitors. Professor Jianzhong Zhang, principal investigator from Peking University People’s Hospital, stated: "Atopic dermatitis is a chronic, relapsing inflammatory and pruritic skin disease that imposes a substantial burden on patients’ quality of life and mental health. In this Phase III study, zemprocitinib demonstrated significant improvements in both skin lesion clearance and itch relief, together with a favorable overall safety profile. We look forward to the potential of zemprocitinib to provide a new oral treatment option for patients with moderate-to-severe atopic dermatitis in China." Dr. Yu Wu, Chief Development Officer of Lynk Pharmaceuticals, commented: "The success of this Phase III study reflects the strength of our long-term strategic focus in immunology and inflammation. These results further validate the potential of zemprocitinib across multiple autoimmune indications and reinforce our clinical development capabilities. We remain committed to advancing regulatory submissions with scientific rigor and high-quality standards." Dr. Zhao-Kui (ZK) Wan, Founder and Chief Executive Officer of Lynk Pharmaceuticals, added: "We are highly encouraged by these positive Phase III results in atopic dermatitis and sincerely thank the patients, investigators, and our internal and external teams for their dedication and professionalism. Following the successful Phase III study in rheumatoid arthritis, this achievement represents another important milestone for zemprocitinib and further reinforces its positioning as a core asset in our pipeline. The favorable balance of efficacy and safety supports its potential differentiated profile in the competitive JAK landscape." **About Zemprocitinib** Zemprocitinib is a highly selective, next-generation JAK1 inhibitor with best-in-class potential, being developed for the treatment of rheumatoid arthritis, ankylosing spondylitis, atopic dermatitis, and vitiligo. Compared with first-generation, less selective JAK inhibitors, zemprocitinib demonstrates significantly greater selectivity for JAK1, which may translate into desirable efficacy while minimizing off-target adverse effects. Zemprocitinib potently and dose-dependently inhibits multiple inflammation-related signaling pathways mediated by JAK1. **About Lynk Pharmaceuticals** Lynk Pharmaceuticals is a clinical-stage biotechnology company founded by senior drug R&D leaders and executives from Pfizer, Merck, and Johnson & Johnson. The company is dedicated to the discovery and development of innovative therapies for immune and inflammatory diseases. Driven by a commitment to address significant unmet medical needs, Lynk Pharmaceuticals aims to deliver differentiated therapies with global impact. To date, the company has independently or jointly advanced multiple innovative drug candidates and successfully completed numerous clinical studies. [Source link ](http://www.prnasia.com/story/archive/4898436_AE98436_0?rand=89749) ``` This content was prepared by our news partner, Cision PR Newswire. The opinions and the content published on this page are the author’s own and do not necessarily reflect the views of Siam News Network ``` ##### You May Also Like [](https://thailandbusinessnews.net/press-release/american-express-opens-new-centurion-lounge-at-tokyos-haneda-airport-2/) ![American Express Opens New Centurion Lounge at Tokyo's Haneda Airport](https://i0.wp.com/r2.thailandbusinessnews.net/2025/07/Main_seating_area_Centurion_Lounge_Haneda_Airport_Photo_courtesy_American.jpg?resize=260%2C140&ssl=1 "American Express Opens New Centurion Lounge at Tokyo's Haneda Airport") - [Press Release](https://thailandbusinessnews.net/category/press-release/) ## American Express Opens New Centurion Lounge at Tokyo's Haneda Airport TAIPEI, July 21, 2025 /PRNewswire/ — On July 16 American Express (NYSE:… - [CISION PRNewswire](https://thailandbusinessnews.net/author/cision/ "View all posts by CISION PRNewswire") - July 21, 2025 [](https://thailandbusinessnews.net/press-release/peoples-daily-survey-reveals-strong-consensus-across-asia-pacific-building-regional-community-reflects-public-aspiration/) ![People's Daily Survey Reveals Strong Consensus across Asia-Pacific: Building Regional Community Reflects Public Aspiration](https://i0.wp.com/r2.thailandbusinessnews.net/2025/10/20251013153716.jpg?resize=260%2C140&ssl=1 "People's Daily Survey Reveals Strong Consensus across Asia-Pacific: Building Regional Community Reflects Public Aspiration") - [Press Release](https://thailandbusinessnews.net/category/press-release/) ## People's Daily Survey Reveals Strong Consensus across Asia-Pacific: Building Regional Community Reflects Public Aspiration BEIJING, Oct. 13, 2025 /PRNewswire/ — A report from People’s Daily: A… - [CISION PRNewswire](https://thailandbusinessnews.net/author/cision/ "View all posts by CISION PRNewswire") - October 13, 2025 [](https://thailandbusinessnews.net/press-release/d-live-announces-record-attendance-at-japan-day-dusseldorf-nrw-2026-around-700000-visitors-celebrated-a-festival-of-japanese-culture-in-dusseldorf-a-spectacular-finale-featuring-traditional-japanes/) ## D.LIVE announces Record attendance at Japan Day Düsseldorf/NRW 2026: Around 700,000 visitors celebrated a festival of Japanese culture in Düsseldorf; A spectacular finale featuring traditional Japanese fireworks DÜSSELDORF, Germany, May 26, 2026 /PRNewswire/ — The 23rd Japan-Tag Düsseldorf/NRW was… - [CISION PRNewswire](https://thailandbusinessnews.net/author/cision/ "View all posts by CISION PRNewswire") - May 26, 2026 ##### Most Read - [![The Sanya EDITION Presents an Island Celebration Experience for Mid-Autumn Festival and China National Day Golden Week](https://secure.gravatar.com/avatar/96e712b5408b51145de772098c3ff3417ce8a11555b7c388d84204c5769f5631?s=40&d=blank&r=g)](https://thailandbusinessnews.net/press-release/the-sanya-edition-presents-an-island-celebration-experience-for-mid-autumn-festival-and-china-national-day-golden-week/ "The Sanya EDITION Presents an Island Celebration Experience for Mid-Autumn Festival and China National Day Golden Week") [The Sanya EDITION Presents an Island Celebration Experience for Mid-Autumn Festival and China National Day Golden Week](https://thailandbusinessnews.net/press-release/the-sanya-edition-presents-an-island-celebration-experience-for-mid-autumn-festival-and-china-national-day-golden-week/ "The Sanya EDITION Presents an Island Celebration Experience for Mid-Autumn Festival and China National Day Golden Week") - [![Dell InnovateFest 2026 Champions Inclusive and Independent Living for Persons with Disabilities Through AI and Cloud-Native Innovation](https://secure.gravatar.com/avatar/96e712b5408b51145de772098c3ff3417ce8a11555b7c388d84204c5769f5631?s=40&d=blank&r=g)](https://thailandbusinessnews.net/press-release/dell-innovatefest-2026-champions-inclusive-and-independent-living-for-persons-with-disabilities-through-ai-and-cloud-native-innovation/ "Dell InnovateFest 2026 Champions Inclusive and Independent Living for Persons with Disabilities Through AI and Cloud-Native Innovation") [Dell InnovateFest 2026 Champions Inclusive and Independent Living for Persons with Disabilities Through AI and Cloud-Native Innovation](https://thailandbusinessnews.net/press-release/dell-innovatefest-2026-champions-inclusive-and-independent-living-for-persons-with-disabilities-through-ai-and-cloud-native-innovation/ "Dell InnovateFest 2026 Champions Inclusive and Independent Living for Persons with Disabilities Through AI and Cloud-Native Innovation") - [![Hisense and Devialet Redefine Home Entertainment](https://i0.wp.com/r2.thailandbusinessnews.net/2025/05/Hisense_s_product_lines__Tuned_Devialet.jpg?fit=600%2C336&ssl=1&resize=40%2C40)](https://thailandbusinessnews.net/press-release/hisense-and-devialet-redefine-home-entertainment/ "Hisense and Devialet Redefine Home Entertainment") [Hisense and Devialet Redefine Home Entertainment](https://thailandbusinessnews.net/press-release/hisense-and-devialet-redefine-home-entertainment/ "Hisense and Devialet Redefine Home Entertainment") - [![Chery Auto to Showcase Nearly 20 Green Technology and Ecosystem Innovations. 2026 Chery International User Summit Opens in October](https://secure.gravatar.com/avatar/96e712b5408b51145de772098c3ff3417ce8a11555b7c388d84204c5769f5631?s=40&d=blank&r=g)](https://thailandbusinessnews.net/press-release/chery-auto-to-showcase-nearly-20-green-technology-and-ecosystem-innovations-2026-chery-international-user-summit-opens-in-october/ "Chery Auto to Showcase Nearly 20 Green Technology and Ecosystem Innovations. 2026 Chery International User Summit Opens in October") [Chery Auto to Showcase Nearly 20 Green Technology and Ecosystem Innovations. 2026 Chery International User Summit Opens in October](https://thailandbusinessnews.net/press-release/chery-auto-to-showcase-nearly-20-green-technology-and-ecosystem-innovations-2026-chery-international-user-summit-opens-in-october/ "Chery Auto to Showcase Nearly 20 Green Technology and Ecosystem Innovations. 2026 Chery International User Summit Opens in October") - [![RIMAN Brings ICD to Rustan's Makati, Expanding Its Premium K-Beauty Presence in the Philippines](https://secure.gravatar.com/avatar/96e712b5408b51145de772098c3ff3417ce8a11555b7c388d84204c5769f5631?s=40&d=blank&r=g)](https://thailandbusinessnews.net/press-release/riman-brings-icd-to-rustans-makati-expanding-its-premium-k-beauty-presence-in-the-philippines/ "RIMAN Brings ICD to Rustan's Makati, Expanding Its Premium K-Beauty Presence in the Philippines") [RIMAN Brings ICD to Rustan's Makati, Expanding Its Premium K-Beauty Presence in the Philippines](https://thailandbusinessnews.net/press-release/riman-brings-icd-to-rustans-makati-expanding-its-premium-k-beauty-presence-in-the-philippines/ "RIMAN Brings ICD to Rustan's Makati, Expanding Its Premium K-Beauty Presence in the Philippines") - [![oneworld Named World's Best Airline Alliance at the 2026 Skytrax Awards](https://secure.gravatar.com/avatar/96e712b5408b51145de772098c3ff3417ce8a11555b7c388d84204c5769f5631?s=40&d=blank&r=g)](https://thailandbusinessnews.net/press-release/oneworld-named-worlds-best-airline-alliance-at-the-2026-skytrax-awards/ "oneworld Named World's Best Airline Alliance at the 2026 Skytrax Awards") [oneworld Named World's Best Airline Alliance at the 2026 Skytrax Awards](https://thailandbusinessnews.net/press-release/oneworld-named-worlds-best-airline-alliance-at-the-2026-skytrax-awards/ "oneworld Named World's Best Airline Alliance at the 2026 Skytrax Awards") ##### Subscribe via Email Enter your email address to subscribe and receive notifications of new posts by email. Email Address Subscribe [](https://thailandbusinessnews.net/press-release/jacc-clinical-electrophysiology-publishes-12-month-outcomes-from-field-medicals-first-in-human-field-pulse-trial-94-2-per-vein-pvi-durability-with-optimized-waveform/) ![JACC: Clinical Electrophysiology Publishes 12-Month Outcomes from Field Medical's First-in-Human Field PULSE Trial: 94.2% Per-Vein PVI Durability with Optimized Waveform](https://i0.wp.com/mmx.prnasia.com/media/MS1690629/Field-Medical-FieldForce-Ablation-System-Next-generation-PFA.jpg?resize=260%2C140&ssl=1 "JACC: Clinical Electrophysiology Publishes 12-Month Outcomes from Field Medical's First-in-Human Field PULSE Trial: 94.2% Per-Vein PVI Durability with Optimized Waveform") ## JACC: Clinical Electrophysiology Publishes 12-Month Outcomes from Field Medical's First-in-Human Field PULSE Trial: 94.2% Per-Vein PVI Durability with Optimized Waveform Late-breaking HRX data advance Field Medical’s "instantaneous ablation"… [](https://thailandbusinessnews.net/press-release/gamesir-announces-official-fortnite-mobile-controller-collection/) ![GameSir Announces Official Fortnite Mobile Controller Collection](https://i0.wp.com/mmx.prnasia.com/media/MS1992163/20260920063028EDT_image_1.jpg?resize=260%2C140&ssl=1 "GameSir Announces Official Fortnite Mobile Controller Collection") ## GameSir Announces Official Fortnite Mobile Controller Collection Officially Licensed Fortnite Edition Mobile Controllers Deliver Console-Level Precision… [](https://thailandbusinessnews.net/press-release/pinglu-canal-connects-rivers-sea-and-new-opportunities/) ## Pinglu Canal connects rivers, sea, and new opportunities BEIJING, Sept. 20, 2026 /PRNewswire/ — A report from People’s Daily The… [](https://thailandbusinessnews.net/press-release/1more-s20-ultra-clip-on-earbuds-launch-as-a-new-all-around-standard-for-open-ear-audio/) ![1MORE S20 Ultra Clip-On Earbuds Launch as a New All-Around Standard for Open-Ear Audio](https://i0.wp.com/mmx.prnasia.com/media/MS1992131/20260920042020EDT_image_1.jpg?resize=260%2C140&ssl=1 "1MORE S20 Ultra Clip-On Earbuds Launch as a New All-Around Standard for Open-Ear Audio") ## 1MORE S20 Ultra Clip-On Earbuds Launch as a New All-Around Standard for Open-Ear Audio SHENZHEN, China, Sept. 20, 2026 /PRNewswire/ — 1MORE S20 Ultra Clip-On Earbuds…